Empowering targeted cancer breakthroughs
Cancer therapies are becoming more and more targeted, so the success of clinical trials depends on selecting the right patient group. Navignostics helps clinical researchers identify the patients that benefit the most from the newly developed therapy approach.
Clinical trials are a massive financial investment, and more than 90% of them fail at a late stage because the newly developed drug helped a too small segment of the patient cohort. Even if a small group benefits greatly but there isn’t a reliable way to identify the group in advance, trials fail to demonstrate the efficacy of a new drug. By preselecting patients who will react most favorably to a new treatment, a drug developer can save a lot of time, money and effort throughout the entire development process. This is where Navignostics comes in.
Most cancer treatments target certain tumor cell proteins or the interplay between tumor and immune cells. Navignostics delivers crucial details on protein features and cell interactions.
At Navignostics, we specialize in spatial single-cell proteomic tumor analysis. We measure standard formalin-fixed, paraffin-embedded (FFPE) tissue samples using highly multiplex protein imaging, which allows us to detect up to 50 proteins simultaneously, at subcellular resolution, in a single tissue section. Our automated data analysis allows us to identify the complex tumor and immune cell types and their interactions, which are key to predicting which patients will respond to a novel therapy.
We have developed a fast and standardized tumor characterization process to help clinicians find the right treatment approach for their individual cancer patients. To meet the diverse needs of our clinical and pharmaceutical partners, we tailor these approaches for efficient yet comprehensive clinical research services. This is how we are able to help you find biomarkers that identify the responders to a novel drug, to improve the success rate of your clinical trials, and to accelerate your drug development process.
We collaborate with our partners at every stage of the drug development process, be it early translational research, biomarker discovery, or clinical trials.
We know we can make a difference. In more than 10 years of translational and clinical research, we have comprehensively characterized tumors of many retrospective and prospective patient cohorts. We have successfully and repeatedly demonstrated that our approach is exceptionally capable of explaining patients’ different reactions to treatment and different overall survival outcomes.
Real change happens when we work together. If you use the Navignostics technologies and clinicians’ patient expertise when making your research discoveries, you can make cancer a solvable problem.
The tools built by Navignostics really start from an underlying clinical need – the team has done a great job in aligning their services along the patients’ needs.
Prof. Dr. med. Dr. phil. Andreas Wicki,
University of Zurich
(NX co-authors: Jana Fischer, Bernd Bodenmiller)
Johanna Wagner et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019 May 16;177(5):1330-1345.e18.
doi: 10.1016/j.cell.2019.03.005
(NX co-authors: Stéphane Chevrier, Bernd Bodenmiller)
Jana Fischer et al. Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. Cell Rep Med. 2023 Mar 21;4(3):100977.
doi: 10.1016/j.xcrm.2023.100977
(NX co-authors: Jana Fischer, Bernd Bodenmiller)
Stéphane Chevrier et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017 May 4;169(4):736-749.e18.
doi: 10.1016/j.cell.2017.04.016
(NX co-authors: Stéphane Chevrier, Bernd Bodenmiller)